[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Platelet-derived growth factor receptor antagonists - Pipeline Insight, 2021

March 2021 | 60 pages | ID: PD23B5A27E7BEN
DelveInsight

US$ 1,500.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
This report can be delivered to the clients within 48 hours

DelveInsight’s, “Platelet-derived growth factor receptor antagonists - Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Platelet-derived growth factor receptor antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Platelet-derived growth factor receptor antagonists Understanding

Platelet-derived growth factor receptor antagonists: Overview

Platelet-derived growth factor receptors belong to class III receptor tyrosine kinases. In human, there are four genes expressing PDGF chains: PDGF-A, B, C and D. PDGFA, PDGFB, PDGFC, and PDGFD genes are located on chromosomes 7, 22, 4, and 11, respectively. Platelet-derived growth factor plays a significant role in cell proliferation and embryonic development and is regulated through the platelet-derived growth factor receptor (PDGFR). Platelet-derived growth factor receptor (PDGFR) is a compelling target for developing therapeutic agents to treat diseases associated with overactivated platelet-derived growth factor (PDGF) signaling and has proved to be particularly encouraging for cancer treatment.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Platelet-derived growth factor receptor antagonists R&D. The therapies under development are focused on novel approaches for Platelet-derived growth factor receptor antagonists.
Platelet-derived growth factor receptor antagonists Emerging Drugs Chapters

This segment of the Platelet-derived growth factor receptor antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Platelet-derived growth factor receptor antagonists Emerging Drugs
  • Lenvatinib: Eisai
Lenvatinib (LENVIMA) is orally available multi-kinase inhibitor and antineoplastic agent that is used in treatment of advanced, metastatic medullary thyroid cancer and refractory renal cell carcinoma. LENVIMA is also used as the first treatment for hepatocellular carcinoma. The drug is in clinical development for other cancers and solid tumors.
  • Quizartinib: Daiichi Sankyo Company
Quizartinib is an orally available small molecule with potential antineoplastic activity. Quizartinib selectively inhibits class III receptor tyrosine kinases, including FMS-related tyrosine kinase 3 (FLT3/STK1), colony-stimulating factor 1 receptor (CSF1R/FMS), stem cell factor receptor (SCFR/KIT), and platelet derived growth factor receptors (PDGFRs), resulting in inhibition of ligand-independent leukemic cell proliferation and apoptosis. Quizartinib is use for acute myeloid leukemia treatment and is in clinical development for Myelodysplastic syndromes and Precursor cell lymphoblastic leukaemia-lymphoma.

Further product details are provided in the report…….

Platelet-derived growth factor receptor antagonists: Therapeutic Assessment

This segment of the report provides insights about the different Platelet-derived growth factor receptor antagonists drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players working on Platelet-derived growth factor receptor antagonists
There are approx. 8+ key companies which are developing the Platelet-derived growth factor receptor antagonists. The companies which have their Platelet-derived growth factor receptor antagonists drug candidates in the most advanced stage, i.e. Phase III include, Eisai.
  • Phases
DelveInsight’s report covers around 8+ products under different phases of clinical development like
  • Late-stage products (Phase III and
  • Mid-stage products (Phase II and
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Platelet-derived growth factor receptor antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Infusion
  • Intradermal
  • Intramuscular
  • Intranasal
  • Intravaginal
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Vaccines
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Platelet-derived growth factor receptor antagonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Platelet-derived growth factor receptor antagonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Platelet-derived growth factor receptor antagonists drugs.

Platelet-derived growth factor receptor antagonists Report Insights
  • Platelet-derived growth factor receptor antagonists Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Platelet-derived growth factor receptor antagonists Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Scenario and Emerging Therapies:
  • How many companies are developing Platelet-derived growth factor receptor antagonists drugs?
  • How many Platelet-derived growth factor receptor antagonists drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for Platelet-derived growth factor receptor antagonists?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Platelet-derived growth factor receptor antagonists therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Platelet-derived growth factor receptor antagonists and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Eisai
  • Daiichi Sankyo Company
  • Jiangsu Hengrui Medicine
  • Boehringer Ingelheim
  • Betta Pharmaceuticals
  • Tyrogenex
  • Pfizer
  • Metagone Biotech
  • Bayer Healthcare
  • AROG Pharmaceuticals
  • Pfizer
  • Molecular Partners
  • Xspray Pharma
Key Products
  • Lenvatinib
  • Quizartinib
  • Famitinib
  • Nintedanib
  • Vorolanib
  • Axitinib
  • MGD 1509
  • Regorafenib
  • Crenolanib
  • AGN-151200
  • Sorafenib nanoparticle formulation
Introduction
Executive Summary
Platelet-derived growth factor receptor antagonists: Overview
  Structure
  Mechanism of Action
Pipeline Therapeutics
  Comparative Analysis
Therapeutic Assessment
  Assessment by Product Type
  Assessment by Stage and Product Type
  Assessment by Route of Administration
  Assessment by Stage and Route of Administration
  Assessment by Molecule Type
  Assessment by Stage and Molecule Type
Platelet-derived growth factor receptor antagonists – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
  Platelet-derived growth factor receptor antagonists companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Platelet-derived growth factor receptor antagonists Collaboration Deals
  Company-Company Collaborations (Licensing / Partnering) Analysis
  Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
  Comparative Analysis
Lenvatinib: Eisai
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II/III)
  Comparative Analysis
Quizartinib: Daiichi Sankyo Company
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
  Comparative Analysis
Drug name: Company name
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
  Comparative Analysis
AGN-151200: Molecular Partners AG
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
  Comparative Analysis
Platelet-derived growth factor receptor antagonists Key Companies
Platelet-derived growth factor receptor antagonists Key Products
Platelet-derived growth factor receptor antagonists- Unmet Needs
Platelet-derived growth factor receptor antagonists- Market Drivers and Barriers
Platelet-derived growth factor receptor antagonists- Future Perspectives and Conclusion
Platelet-derived growth factor receptor antagonists Analyst Views
Platelet-derived growth factor receptor antagonists Key Companies
Appendix

LIST OF TABLES

Table 1 Total Products for Platelet-derived growth factor receptor antagonists
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products


LIST OF FIGURES

Figure 1 Total Products for Platelet-derived growth factor receptor antagonists
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products


More Publications